Replies to post #3935 on FDA Plays

[pcrutch]

2 things:

they have the reverse split and shelf in place for several reasons

a) if they can't find a good licensing deal with a partner, they still need to start the trial in a timely manner.

b) r/s is there in the event they need a flotation device to stay on NASDAQ and get the price to levels where institutions will buy in more significant quantities.

i think ASCO will be more than enough to send the stock over $1 permanently. lets just hope no R/S before the presentation.